Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.78 |
| ▸ | CA2 | P00918 | 5/20 | 0.78 |
| ▸ | CA12 | O43570 | 4/20 | 0.78 |
| ▸ | CA9 | Q16790 | 4/20 | 0.78 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672768 | 0.88 | CA2 (1.00) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL14726222 | 0.88 | MAPT (0.65) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL6371005 | 0.82 | RAB9A (0.75) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL14726346 | 0.82 | IDH1 (0.68) | CA1CA2CA12CA9IDH1 | |
| SCHEMBL15132987 | 0.80 | CA12 (0.66) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL14726217 | 0.78 | CA12 (0.74) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL1645328 | 0.74 | CA1 (1.00) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL14726218 | 0.74 | CA1 (0.72) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL5525112 | 0.73 | RAB9A (0.62) | CA1CA2CA12CA9RAB9A | |
| SCHEMBL6117229 | 0.73 | RAB9A (0.61) | CA1CA2CA12CA9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | UNIVERSITETET I OSLO (NO) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | CA9, CA2, CA4 | CA1 5/4885CA2 2/4885CA12 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.